18
Treatment
Figure 5. Recommendations (Class 1 and 2a) for Patients at
Risk of HF (Stage A) and Those With Pre-HF (Stage B)
Patients with
hypertension
Optimal control of BP
(1)
Patients with type 2
diabetes and CVD or
high risk for CVD
Patients with
exposure to
cardiotoxic agents
SGLT2i
(1)
Multidisciplinary
evaluation for
management
(1)
Patients with CVD
First-degree relatives
of patients with
genetic or inherited
cardiomyopathies
Optimal management
of CVD
(1)
Genetic screening and
counseling
(1)
Continue lifestyle modifications and management
strategies implemented in Stage A, through Stage B
Patients at risk
for HF
Natriuretic peptide
biomarker screening
(2a)
Validated multivariable
risk scores
(2a)
Patients at risk
for HF
Class 1 and Class 2a recommendations for patients at risk for HF (stage A) and those with
pre-HF (stage B) are shown. Management strategies implemented in patients at risk for HF
(stage A) should be continued though stage B.
